Parkinson's Disease and Post-COVID-19 Syndrome: The Parkinson's Long-COVID Spectrum

Valentina Leta^{1

2}, Mayela Rodríguez-Violante^{3

4}, Arturo Abundes^{3

4}, Katarina Rukavina^{1

2}, James T Teo^{1

5}, Cristian Falup-Pecurariu^{6

7}, Laura Irincu^{6

7}, Silvia Rota^{1

2}, Roongroj Bhidayasiri^{8

9}, Alexander Storch^{10

11}, Per Odin¹², Angelo Antonini¹³, Kallol Ray Chaudhuri^{1

2}

Affiliations

¹ King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
² Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.
³ Clinical Neurodegenerative Research Unit, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
⁴ Movement Disorder Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
⁵ King's College Hospital National Health Service Foundation Trust, London, UK.
⁶ Department of Neurology, Faculty of Medicine, Transilvania University of Brașov, Brașov, Romania.
⁷ Department of Neurology, County Emergency Clinic Hospital, Brașov, Romania.
⁸ Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
⁹ The Academy of Science, The Royal Society of Thailand, Bangkok, Thailand.
¹⁰ German Center for Neurodegenerative Diseases Rostock/Greifswald, Rostock, Germany.
¹¹ Department of Neurology, Translational Neurodegeneration Section "Albrecht Kossel," University of Rostock, Rostock, Germany.
¹² Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
¹³ Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.

Valentina Leta et al. Mov Disord. 2021 Jun.

. 2021 Jun;36(6):1287-1289.

doi: 10.1002/mds.28622. Epub 2021 Apr 28.

¹ King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
² Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.
³ Clinical Neurodegenerative Research Unit, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
⁴ Movement Disorder Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
⁵ King's College Hospital National Health Service Foundation Trust, London, UK.
⁶ Department of Neurology, Faculty of Medicine, Transilvania University of Brașov, Brașov, Romania.
⁷ Department of Neurology, County Emergency Clinic Hospital, Brașov, Romania.
⁸ Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
⁹ The Academy of Science, The Royal Society of Thailand, Bangkok, Thailand.
¹⁰ German Center for Neurodegenerative Diseases Rostock/Greifswald, Rostock, Germany.
¹¹ Department of Neurology, Translational Neurodegeneration Section "Albrecht Kossel," University of Rostock, Rostock, Germany.
¹² Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
¹³ Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.

No abstract available

Keywords: COVID-19; Long COVID; Parkinson's disease; Post-COVID-19 syndrome; SARS-CoV-2.

References

1. Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's disease patients affected by COVID‐19. Mov Disord 2020;35(6):905–908. - PMC - PubMed
1. Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Narayanan NS. Coronavirus disease 2019 case fatality and Parkinson's disease. Mov Disord 2020;35(11):1914–1915. - PMC - PubMed
1. Sulzer D, Antonini A, Leta V, et al. COVID‐19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis 2020;6:18. 10.1038/s41531-020-00123-0 - DOI - PMC - PubMed
1. Artusi CA, Romagnolo A, Imbalzano G, et al. COVID‐19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism Relat Disord 2020;80:7–9. 10.1016/j.parkreldis.2020.09.008 - DOI - PMC - PubMed
1. Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID‐19 on Parkinson's disease clinical features: a community‐based case‐control study. Mov Disord 2020;35(8):1287–1292. - PMC - PubMed